10x Genomics, Inc. ($TXG) Stock Forecast: Down 5.0% Today

What is 10x Genomics, Inc.?

10x Genomics Inc (TXG) is a biotechnology company specializing in genomics and single-cell analysis technologies. The company has recently experienced significant growth and positive earnings reports, leading to a surge in its stock price.

Why is 10x Genomics, Inc. going down?

TXG stock is down 5.0% on Mar 6, 2026 16:46

• The bearish movement in TXG's stock price could be attributed to the CEO selling a significant number of shares, which might have raised concerns among investors about the company's future prospects.
• The filing of a Form 144 by an affiliate proposing to sell Class A Common stock could have also contributed to the downward pressure on the stock, signaling potential insider sentiment or profit-taking.
• Despite the recent strong earnings and raised price targets by analysts, the selling activity by key company figures and affiliates may have created uncertainty among investors, leading to the bearish market movement in TXG today.
• The influx of RSUs being granted to company directors and officers, while designed for retention and performance alignment, could also have added to the selling pressure on the stock as recipients may choose to liquidate some of their holdings.

TXG Price Chart

TXG Technical Analysis

TXG News

10x genomics CEO Saxonov sells $367,096 in shares

Serge Saxonov, CEO of 10x Genomics Inc, sold 16,152 shares of Class A Common Stock for approximately $367,096 on March 2, 2026, and an additional 2,750 shares on March 3, 2026. These sales occurred as the stock traded near its 52-week high after a significant 105% gain over the past year. The company recently reported strong Q4 2025 earnings, leading analysts like Stifel and Canaccord Genuity to raise their price targets.

https://m.investing.com/news/insider-trading-news/10x-genomics-ceo-saxonov-sells-367096-in-shares-93CH-4543240?ampMode=1

10x Genomics (TXG) CEO sells shares and makes stock gift

10x Genomics CEO Serge Saxonov reported selling 16,152 shares of Class A common stock and making a gift of 2,750 shares, according to a recent SEC Form 4 filing. The share sales occurred on March 2, 2026, under a Rule 10b5-1 trading plan, at weighted average prices of $22.6690 and $23.1781. Following these transactions, Saxonov directly holds over 1.2 million shares and also has indirect holdings through several trusts for which he serves as trustee.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-1edb8cf92fc8.html

10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award

10x Genomics CFO Adam Taich has been granted 106,579 Restricted Stock Units (RSUs) in a new equity award, as reported in a recent SEC Form 4 filing. This award, given at no cash cost, increases his directly held beneficial ownership to 394,996 shares. The RSUs are designed for retention and performance alignment, vesting quarterly over time, with the first installment on February 21, 2026.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-cfc80dd18105.html

88,816 RSUs awarded to 10x Genomics (TXG) director Hindson

Benjamin J. Hindson, a director and officer of 10x Genomics, Inc. (TXG), was granted 88,816 restricted stock units (RSUs) as reported in a recent Form 4 SEC filing. These RSUs, valued at $0.00 per share, will vest quarterly starting February 21, 2026, provided Hindson remains a service provider. After this grant, his total directly held Class A Common Stock, including RSUs, amounts to 513,595 shares.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-beee8fe73f8b.html

TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG)

An affiliate of 10x Genomics, Inc. (NASDAQ: TXG) has filed a Form 144, proposing to sell Class A Common stock. The filing details several vested RSU lots, including quantities of 16,152, 4,879, 3,265, 3,723, 8,156, and 4,977 shares, which are tied to issuer vesting events. JP Morgan Securities LLC is listed as the broker for these transactions on the Nasdaq market.

https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-75689f6b760b.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

10x Genomics, Inc. Price History

08.07.2025 - TXG Stock was down 6.8%

• Despite surpassing Q2 earnings and revenue estimates significantly, TXG experienced a bearish movement.
• Investors might have had high expectations already priced into the stock, leading to a sell-off post-earnings.
• The market might be reacting to forward-looking guidance or other factors not captured in the earnings report, causing the bearish movement.
• This could be a classic case of "buy the rumor, sell the news" scenario, where investors take profits after a positive earnings surprise.

25.01.2026 - TXG Stock was up 5.1%

• TXG experienced a strong bullish movement today, potentially driven by positive developments in its research and development pipeline.
• Despite the challenges faced by the overall life sciences sector in raising capital, TXG's ability to secure funding or announce breakthroughs may have boosted investor confidence.
• The bullish movement could also be attributed to market expectations of TXG's future growth potential and innovation within the industry, leading to increased investor interest and buying activity.

13.01.2026 - TXG Stock was up 10.3%

• Recently, the company demonstrated narrowed losses in 2025, signaling improved profitability and reduced operating expenses, potentially enhancing investor confidence in its financial stability.
• Despite conservative revenue forecasts for 2026 and expectations of modest growth, the company appears to be focusing on profitability and sustainable development, a strategy that investors seem to favor.
• Favorable perceptions of the company's strong cash reserves and strategic partnerships are likely driving positive expectations for its future performance, influencing the upward movement of its stock price today.

21.09.2025 - TXG Stock was up 5.7%

• 10x Genomics (TXG) stock experienced a robust bullish movement, rising by 11.1%.
• The recent above-average trading volume suggests growing investor interest in the company's stock.
• Despite the positive performance, there are concerns about the sustainability of this strength in the short term given recent trends in earnings estimate revisions, which may prompt caution among investors.
• It is advisable for investors to closely track any updates in earnings estimates to assess the future direction of TXG's stock price.

06.02.2026 - TXG Stock was down 5.0%

• The bearish movement in TXG's stock price could be attributed to the CEO selling a significant number of shares, which might have raised concerns among investors about the company's future prospects.
• The filing of a Form 144 by an affiliate proposing to sell Class A Common stock could have also contributed to the downward pressure on the stock, signaling potential insider sentiment or profit-taking.
• Despite the recent strong earnings and raised price targets by analysts, the selling activity by key company figures and affiliates may have created uncertainty among investors, leading to the bearish market movement in TXG today.
• The influx of RSUs being granted to company directors and officers, while designed for retention and performance alignment, could also have added to the selling pressure on the stock as recipients may choose to liquidate some of their holdings.

09.04.2025 - TXG Stock was down 1.7%

• The reported Q1 loss by TXG may have raised concerns among investors about the company's financial health, leading to a bearish movement in the stock.
• Despite topping revenue estimates, the larger-than-expected loss could have overshadowed the positive revenue performance, contributing to the downward trend in TXG's stock price.
• Investors might be cautious about the future prospects of TXG, waiting for more clarity on the factors behind the reported loss and its potential impact on the company's growth trajectory.

07.10.2025 - TXG Stock was up 11.4%

• The strong bullish movement in TXG today can be attributed to the company's impressive Q3 earnings report, where they beat revenue estimates by 4.64%.
• Investors seem to be optimistic about TXG's future prospects, as the company also reported a positive earnings surprise of 18.52% for the quarter.
• The market's positive reaction indicates confidence in TXG's ability to continue delivering strong financial performance and innovation in the biotechnology sector.

29.04.2025 - TXG Stock was up 5.4%

• Analysts have established an average price target for TXG, signaling a potential upside of 43.1% and demonstrating favorable sentiment toward the stock.
• Upward revisions in earnings estimates for TXG may have played a role in the market's bullish movement.
• Investor confidence in TXG's growth prospects and advancements in gene sequencing technology likely contributed to the optimistic market sentiment.

14.04.2025 - TXG Stock was down 5.0%

• Despite analysts forecasting a potential upside of 55.9% for TXG, the stock exhibited a bearish movement today.
• The Q1 earnings report revealed a 20% earnings surprise and 16.24% revenue beat, which could have initially fueled positive investor sentiment.
• However, undisclosed factors within the report likely triggered a negative market response, resulting in today's bearish movement in TXG.
• Concerns about the company's future prospects or broader market conditions may be contributing to the decline in TXG's stock price.

17.01.2026 - TXG Stock was up 5.1%

• The bullish movement in TXG's stock today can be attributed to the company's impressive financial performance in 2025, with significantly narrowed losses and a strategic shift towards profitability.
• The cautious revenue guidance for 2026, projecting modest growth, might have initially raised concerns among investors, but the market likely responded positively to the company's strong cash reserves and strategic partnerships.
• Despite the broader underperformance of the life sciences tools and services sector and economic uncertainties related to tariffs and corporate tax changes, TXG's focus on improved profitability seems to have resonated well with investors, driving the bullish movement in its stock.

09.00.2026 - TXG Stock was up 5.2%

• Analysts raising price targets for TXG led to a 2.5% increase in its stock price, indicating growing optimism in the company's future prospects.
• The market reaction, settling for a 0.7% rise, suggests that while the news was viewed positively, it was not seen as a game-changer for the volatile stock.
• Factors such as recovering end markets and diminishing headwinds contributed to the bullish movement in TXG's stock price.
• The overall sentiment towards TXG seems positive, with analysts expecting a bright outlook for the company in early 2026.

30.09.2025 - TXG Stock was down 5.2%

• The bearish movement in TXG today could be attributed to profit-taking by investors who may have been anticipating a positive earnings report.
• Despite expectations of beating earnings estimates, market sentiment may have shifted due to broader economic concerns or sector-specific challenges impacting biotech stocks.
• It's possible that some investors are taking a cautious approach ahead of the earnings release, leading to a temporary dip in TXG's stock price.